In the News
Empire Genomics, a firm in the field of personalized medicine specializing in oncological molecular genomic testing, has acquired an exclusive license from Cornell for a novel DNA biomarker to develop a diagnostic test for diagnosing and determining treatment for patients with neuroendocrine prostate cancer (NEPC).
Herb Aldwinkle’s lab in upstate New York has developed fire blight resistant root stocks that popular, yet susceptible apple varieties can be grafted to while still keeping the character of the variety intact.
Student entrepreneurs from Cornell University captured the LES Foundation 2013 International Graduate Student Business Plan Competition’s $10,000 Grand Prize for their technology spinout, Empire Robotics.
A study, reported in the April 30 issue of Cancer Discovery, offers hope that a drug based on two potentially therapeutic proteins might help keep human cancer at bay and from metastasizing.
Cancer is typically thought to develop after genes gradually mutate over time, finally overwhelming the ability of a cell to control growth. But a new closer look at genomes in prostate cancer by an international team of researchers reveals that, in fact, genetic mutations occur in abrupt, periodic bursts, causing complex, large scale reshuffling of DNA driving the development of prostate cancer.
Cornell Tech, the applied sciences graduate school that Cornell University has planned for Roosevelt Island, has received a gift of $133 million that will help it offer an unusual two-year, two-degree master’s program.
Cornell University researchers have created a pore in “Cornell Dots”—brightly glowing nanoparticles nicknamed C-Dots—that can carry medicine. This new and improved nanoscale courier may help light up cancer cells and provide a new patient-friendly, viable option to battle cancer.
A previously unknown function of a family of enzymes familiar to biologists may contribute to scientists’ understanding of signaling molecules involved in the body’s immune response and could help in the treatment of such diseases as rheumatoid arthritis and cancer.
Pacific Biosciences of California, Inc. announced the launch of the PacBio® RS II — a new Single Molecule, Real-Time (SMRT®) DNA Sequencing System that provides the industry's highest consensus accuracy and longest read lengths, with double the throughput from the previous version of the system.
Cornell's Alexander Gaeta, School of Applied and Engineering Physics, conducts research focusing on using light for imaging and other processing typically done today with electrons.
VaxLogic LLC, a wholly owned subsidiary of PharmLogic LLC, has entered into a license agreement with Cornell University to develop and commercialize new vaccines to combat addictions, including nicotine and other drugs.
A biotechnology startup has developed a technology platform it claims does a better job of indicating the effect drugs would have on humans in the preclinical phase of development than animals.
Tetragenetics, a 2012 Gates Foundation phase II grant recipient and an emerging biotechnology company focused on particle-based vaccines and expression of ion channel drug targets, has entered into a collaboration agreement with an option for an exclusive license with Pfizer.
Thousand Oaks biotech Amgen Inc. has signed a licensing deal which gives it exclusive access to an antigen being developed by Massachusetts startup Tetragenetics Inc.
Tetragenetics Inc. in Cambridge, Mass., an early-stage biotech that has developed a new way to produce biologic drugs, has announced an $826,000 grant and new partnerships with two major drug companies.
A panel of five experts from big and small pharma as well as academia were joined on February 26 by co-host Campbell Alliance, which provided an advance look at its Survey of Dealmaker Intentions, due for rollout at the BIO Annual Meeting in Chicago later this month.
The world's first diagnostic test for a culprit in 'kennel cough' is now available at Cornell's Animal Health Diagnostic Center (AHDC).
Physicians at Weill Cornell Medical College and biomedical engineers at Cornell announced that with the help of living cells, they had successfully created an exact copy of the human ear that looks and behaves like the natural one.
After deciding from over 1,000 different names, Cornell University christened two new grape varieties: 'Arandell' and 'Aromella' on February 7 at Viticulture 2013, the premier grape and wine industry conference in Rochester, NY.
Control of blood and iron disorders affecting patients worldwide centers on regulating iron and blood cell production.
A research team led by Weill Cornell Medical College investigators may have solved a major issue of expanding adult hematopoietic stem cells (HSCs) outside the human body for clinical use in bone marrow transplantation — a critical step towards producing a large supply of blood stem cells needed to restore a healthy blood system.
Cornell startup, Alcyone Lifesciences, is collaborating with DNAtrix to investigate their Microcatheter System for delivery of therapeutics for brain tumors.
A new method for making puffed rice that retains nutrients and allows producers to fortify cereals with vitamins and protein.
Angiocrine Bioscience, developers of research and therapeutic products based on a portfolio of stem cell- and endothelial cell-related technologies, has raised $4 million.
"Iron Lady" is the first tomato to resist three major fungal diseases -- early blight, late blight and Septoria leaf spot -- plaguing New York's growers for years.
Weill Cornell research offers patients hope for new treatments for an aggressive and common lymphoma.
Appinions set as end-to-end influencer marketing solution with new executive hires.
Discovery of the atomic structure of a ligand-free G protein-coupled receptor (GPCR) will held design more effective drugs.
For archived news items, click here.